In vivo studies using the TGFα‐ and bleomycin‐induced mouse models of pulmonary fibrosis demonstrate that barasertib, a known AURKB inhibitor, attenuates fibroproliferation, myofibroblast survival, and ECM deposition in established and ongoing pulmonary fibrosis. Here, TGFA is linked to pulmonary fibrosis.